MetaCap

Arbutus Biopharma Corporation (ABUS)

NASDAQ: ABUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

4.02-0.05 (-1.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ABUS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$616.24M
52-week range
3.50 – 5.45
Day range
3.97 – 4.09
Volume / Avg
2.99M / 4.98M
Beta
—

52-week range

$3.50$5.45

ABUS stock today

On Nov 20, ABUS ended the session at $4.02, shedding $0.05 (1.23%), versus the S&P 500's 3.70% decline. Shares are 26.2% below their 52-week high of $5.45, set on Aug 21, 2026 and 14.9% above the 52-week low of $3.50, in the middle of the past year's range. ABUS is down 16.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 6.7%.

Arbutus Biopharma trades at 3.6x its trailing twelve-month earnings per share of $1.12.

Summary generated from market data by MetaCap's automated system. Methodology

About Arbutus Biopharma

Company profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Lindsay Androski J.D., M.B.A.
Headquarters
Warminster, PA
Employees
19

Financial highlights

Full financials

In fiscal 2025, Arbutus Biopharma generated $14.1 million in revenue, up 128.2% from fiscal 2024. Arbutus Biopharma reported a net loss of $33.5 million, compared with a loss of $69.9 million a year earlier. Operating margin was -271.0%.

Arbutus Biopharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$14.08M$6.17M$18.14M$39.02M$10.99M
Growth+128.21%-65.98%-53.51%+255.11%+58.92%
Net income$-33.50M$-69.92M$-72.85M$-69.46M$-76.25M
EPS (diluted)$-0.17$-0.38$-0.44$-0.46$-0.83

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$5.32+32.34%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$0.30 vs —

ABUS news

All ABUS news

Arbutus Biopharma peers

Health Care sector
ABUS peer companies
CompanyPrice% ChgMarket capCompare
JANXJanux Therapeutics Inc.10.08-2.04%$616.73Mvs ABUS
OLMAOlema Oncology Inc.7.02-1.82%$615.00Mvs ABUS
KURAKura Oncology Inc.6.91-5.99%$634.88Mvs ABUS
SGMTSagimet Biosciences Inc. Series A9.08-5.61%$648.02Mvs ABUS
ANNXAnnexon Inc.3.10-9.09%$591.37Mvs ABUS
IMMXImmix Biopharma Inc.6.96-1.14%$583.33Mvs ABUS
NVCTNuvectis Pharma Inc.19.39-2.27%$666.80Mvs ABUS
APMDApnimed Inc.16.09-6.70%$669.84Mvs ABUS

Indexes, lists and sector

Arbutus Biopharma stock FAQ

What is Arbutus Biopharma's stock price today?

ABUS last traded at $4.02 as of Nov 20, 4:00 PM EST, down 1.23% on the day. Prices are delayed at least 15 minutes.

Does Arbutus Biopharma pay a dividend?

No. Arbutus Biopharma does not currently pay a regular cash dividend.

What is ABUS's P/E ratio?

ABUS trades at a trailing P/E ratio of 3.59.

Who is Arbutus Biopharma's CEO?

Ms. Lindsay Androski J.D., M.B.A. is the chief executive officer of Arbutus Biopharma Corporation, which has about 19 employees.

Has ABUS ever split its stock?

Yes. The most recent ABUS stock split was a 1-for-5 split on Nov 4, 2010.

What is the ABUS 52-week high?

The 52-week high for ABUS is $5.45 and the 52-week low is $3.50. The stock is currently 26.2% below its high.

Compare ABUS